Categories
Change Password!
Reset Password!
Treatment of refractory stable vitiligo with microneedling plus topical pimecrolimus results in more significant patient improvement when compared to topical pimecrolimus alone.
A randomized clinical trial published in Dermatology Research and Practice depicted the safety and effectiveness of the combination of microneedling and 1% pimecrolimus cream to treat resistant vitiligo lesions of the limbs. Fariba Iraji et al. undertook this study to determine the efficacy of the combination of microneedling and 1% topical pimecrolimus vs the sole usage of 1% topical pimecrolimus for vitiligo management.
The study investigated 32 lesions from 16 vitiligo patients. Each person had 2 similar lesions in the limb area, and each lesion was considered a separate therapy group. The left or right side of the participant’s lesion was randomly allocated to receive microneedling in combination with topical pimecrolimus therapy for 3 months, while the other side was treated with only topical pimecrolimus therapy.
Digital photography was done at the baseline and biweekly for 3 months following therapy and 6 months follow-up. Using patient satisfaction questionnaires, Dermatology life Quality Index (DLQI) questionnaires, and two independent dermatologists comparing the improvement rate for each group, the results were assessed.
Unsatisfactory results were reported with 1% topical pimecrolimus therapy. On the other hand, microneedling plus 1% topical pimecrolimus therapy led to a more favorable overall outcome. Only 1 participant experienced mild skin irritation as an adverse reaction of topical pimecrolimus.
Thus, microneedling in combination with topical pimecrolimus is beneficial to treat resistant vitiligo lesions of the limbs.
Dermatology Research and Practice
Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial
Fariba Iraji et al.
Comments (0)